We set out to evaluate the effect of postnatal exposure to tenofovir-containing antiretroviral therapy on bone mineral density among breastfeeding women living with HIV.
IMPAACT P1084s is a sub-study of the PROMISE randomized trial conducted in four African countries (ClinicalTrials.gov number NCT01066858).
IMPAACT P1084s enrolled eligible mother-infant pairs previously randomised in the PROMISE trial at one week after delivery to receive either maternal antiretroviral therapy (Tenofovir disoproxil fumarate / Emtricitabine + Lopinavir/ritonavir–maternal TDF-ART) or administer infant nevirapine, with no maternal antiretroviral therapy, to prevent breastmilk HIV transmission. Maternal lumbar spine and hip bone mineral density were measured using dual-energy x-ray absorptiometry (DXA) at postpartum weeks 1 and 74. We studied the effect of the postpartum randomization on percent change in maternal bone mineral density in an intention-to-treat analysis with a t-test; mean and 95% confidence interval (95%CI) are presented.
Among 398/400 women included in this analysis, baseline age, body-mass index, CD4 count, mean bone mineral density and alcohol use were comparable between study arms. On average, maternal lumbar spine bone mineral density declined significantly through week 74 in the maternal TDF-ART compared to the infant nevirapine arm; mean difference (95%CI) -2.86 (-4.03, -1.70) percentage points (p-value <0.001). Similarly, maternal hip bone mineral density declined significantly more through week 74 in the maternal TDF-ART compared to the infant nevirapine arm; mean difference -2.29% (-3.20, -1.39) (p-value <0.001). Adjusting for covariates did not change the treatment effect.
Citation: Stranix-Chibanda L, Tierney C, Sebikari D, Aizire J, Dadabhai S, Zanga A, et al. (2021) Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. PLoS ONE 16(2): e0246272. https://doi.org/10.1371/journal.pone.0246272
Editor: Esteban Martinez, Hospital Clinic de Barcelona, SPAIN
Received: May 25, 2020; Accepted: January 9, 2021; Published: February 5, 2021
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Data Availability: The individual level data cannot be made publicly available due to the ethical restrictions in the study’s informed consent documents and in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network’s approved human subjects protection plan; public availability may compromise participant confidentiality. However, data are available to all interested researchers upon request to the IMPAACT Statistical and Data Management Centre’s data access committee by email to email@example.com or firstname.lastname@example.org. This committee reviews and responds to requests for data, obtains necessary approvals from IMPAACT leadership and the NIH, arranges for signature of a Data Use Agreement, and releases the requested data.
Funding: Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT Leadership and Operations Center), UM1AI068616 (IMPAACT Statistical and Data Management Center) and UM1AI106716 (IMPAACT Laboratory Center), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Antiretrovirals were provided free of charge for the PROMISE P1084s study by AbbVie, Gilead Sciences, and GlaxoSmithKline. Bone density scanners were provided for the PROMISE P1084s study by Gilead Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Bone mineral density (BMD) peaks in early adulthood after which it is lost gradually at a rate of approximately 1% per year [1, 2]. Low BMD, either osteopenia (BMD Z- or T-scores between -1 to -2.5) or osteoporosis (scores <-2.5), may result in low-trauma bone fractures; and women are at increased risk for osteoporosis or osteopenia compared to men. Lifestyle factors that increase this risk include lack of exercise, cigarette smoking, high alcohol intake, and low intake of dietary calcium and vitamin D.
Some of these traditional lifestyle factors for low BMD occur in people living with HIV [3–6]. However, both HIV infection itself and antiretroviral therapy (ART) are also associated with an increased risk of low BMD [5, 7–13], and an accelerated BMD decline is seen in the first year following immediate compared to deferred initiation of ART . Tenofovir disoproxil fumarate (TDF) was implicated to have a relatively greater adverse impact on BMD when compared to other antiretroviral drugs , although reduced BMD has been observed with other agents [15, 16]. Low BMD was reported in children, adolescents and adults on tenofovir-containing ART (TDF-ART)  with possible improvement after regimen switch in adults [18–20]. Significant BMD decline was also seen in adults without HIV receiving TDF-based pre-exposure prophylaxis (PrEP) [21, 22] and treatment for chronic hepatitis B infection [23, 24]. BMD loss with PrEP use occurred within months of initiation and then stabilized, returning to baseline levels upon removal of the drug .
Female sex appears to be independently associated with low BMD among adults with HIV on ART . In women, BMD is also affected by reproductive hormones; there is a well-documented transient loss during pregnancy and lactation [1, 2, 26–28]. Despite the involvement of regulatory homeostatic pathways, BMD decreases by about 3% during pregnancy [1, 2]. During the initial six months of lactation, there is a further 5%–6% decrease which generally resolves to pre-pregnancy levels within three months following cessation of breastfeeding [29–31]. The rate of bone lost each year in pre-menopausal women enrolled in the US-based Women’s Interagency HIV Study (WIHS) was approximately 0.4–0.8% and was not associated with HIV infection status. However, long-term study of the aging WIHS cohort revealed that women living with HIV bear a higher 10-year fracture incidence compared to uninfected women (adjusted Hazard Ratio: 1.32, 95%CI: 1.04, 1.69) .
Breastfeeding beyond 12 months is standard for women in Sub-Saharan Africa, regardless of HIV status. Potential effects of prolonged lactation and high parity on BMD and fracture risk are not resolved [2, 27, 33–35]. Most populations studied to date were from developed countries where parity is not high, breastfeeding is not prolonged and nutrition is generally adequate . Nabwire et al observed accentuated bone loss after 14 weeks of breastfeeding in Ugandan women with HIV on life-long ART compared to women without HIV . The randomized design of the PROMISE study provided an ideal opportunity to further contribute towards clarifying the relative role of ART in the observed bone loss among women living with HIV. PROMISE participants were women with HIV infection and high CD4 counts in Sub-Saharan Africa who did not meet country criteria for ART initiation at the time of the postpartum randomization to take TDF-ART or no ART while breastfeeding. The IMPAACT P1084s Bone and Kidney Health sub-study of PROMISE aimed to evaluate in a breastfeeding population the effect of postpartum exposure to TDF-ART on change in maternal BMD from delivery to 18 months, when BMD restitution following cessation was expected to have taken place. The full protocol is available on the Network website https://www.impaactnetwork.org/studies/p1084s
Materials and methods
The PROMISE trial enrolled 3747 pregnant women living with HIV along with their infants to determine the optimal antiretroviral strategy to prevent perinatal and postpartum transmission of HIV from mother to child and preserve maternal health and infant survival in 15 countries across different health settings [38–41]. The PROMISE Antepartum randomization was to open-label Zidovudine mono-drug prophylaxis or Zidovudine/Lamivudine/Lopinavir/ritonavir ART (see S1 Fig–PROMISE study design).
The PROMISE Postpartum Component randomized healthy women with HIV and high CD4 counts intending to breast feed and their uninfected, healthy infants weighing at least 2kg one week after delivery to receive either open-label maternal ART (Tenofovir disoproxil fumarate/Emtricitabine + Lopinavir/ritonavir–‘TDF-ART’) or administer infant nevirapine prophylaxis without maternal ART (iNVP) throughout the period of breastfeeding to prevent breastmilk transmission. At the time PROMISE was conducted, enrolled women did not meet the criteria to initiate ART for their own health and life-long ART was not yet standard for pregnant women. The Bone and Kidney Health sub-study offered postpartum co-enrolment to a sub-set of women enrolled in PROMISE with no prior TDF exposure during pregnancy in four African countries with capacity for BMD evaluation; Malawi, South Africa, Uganda and Zimbabwe; with a target sample size of 400.
On July 6, 2015 PROMISE sites were notified that all participants should be offered ART based on the results of the Strategic Timing of AntiRetroviral Treatment (START) study  which demonstrated a significant benefit to beginning ART, including in patients with high CD4 counts. Analyses for P1084s are thus based on data collected at visits through the date of notification.
After obtaining maternal consent, P1084s sub-study entry occurred immediately (same day) after PROMISE Postpartum randomization on postpartum day 6–14. Participants were followed at 6, 26 and 74 postpartum weeks. Data collected throughout follow-up included socio-demographic information, medical history, HIV-related medical information including viral load, ART adherence assessment, smoking status, alcohol intake status, physical activity level, dietary intake, renal function, concomitant medications including contraceptive use and breastfeeding status. The protocol did not specify nutritional supplements. Weight and height measurements were conducted by trained study staff according to standardized measurement guidance. Maternal participants randomized to iNVP (no ART) who subsequently met immunological or clinical criteria to initiate ART for their own health were immediately started on ART and remained in observational follow-up.
Bone mineral density assessment
Maternal BMD was measured at the lumbar spine and hip by dual-energy x-ray absorptiometry (DXA). The baseline measurement was scheduled at postpartum week one (day 5–21) and repeated at postpartum week 74 (+/-6 weeks), unless the participant was pregnant. Standardized procedures for obtaining the scan were followed to minimize differences between the study sites–all scanners were Hologic models that were cross-calibrated with a phantom, each technician underwent webinar training and quality review of their first scan, and DXA scans were centrally analyzed at the University of California San Francisco Department of Radiology and Biomedical Imaging. DXA operators and readers were blinded to study treatment assignment.
The study was funded by the National Institutes of Health (ClinicalTrials.gov number NCT01066858). Written informed consent was obtained from each sub-study participant. Study conduct adhered to international guidelines, and the sub-study was approved by an institutional review board or ethics committee at each site and corresponding collaborating institutions in the United States.
Ethics committees and institutional review boards that approved this study include—MUJHU/Kampala, Uganda: The Joint Clinical Research Centre (JCRC) IRB, the National Drug Authority in Uganda and the Johns Hopkins Medical Institutions (JHMI) IRB in the U.S.; Wits RHI Shandukani CRS and Soweto IMPAACT CRS, Johannesburg, South Africa: University of Witwatersrand Human Ethics Research Committee (Medical), Medicines Control Council (South African Health Products Regulatory Authority in February 2018); FAM-CRU CRS, Cape town, South Africa: Health Research Ethics Committee (HREC), Faculty of Health Sciences, Stellenbosch University and Medicines Control Council (South African Health Products Regulatory Authority in February 2018); Durban Paediatric HIV CRS, Durban, South Africa: University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee, Medicines Control Council (South African Health Products Regulatory Authority in February 2018);George CRS, Lusaka, Zambia: University of North Carolina (UNC) at Chapel Hill Biomedical IRB and University of Zambia Biomedical Research Ethics Committee (UNZABREC); Harare, Seke North and St. Mary’s sites, Zimbabwe: Medical Research Council of Zimbabwe(MRCZ), Research Council of Zimbabwe (RCZ), Medicine Control Authority of Zimbabwe (MCAZ), Joint Parirenyatwa group of Hospitals/University of Zimbabwe College of Health Sciences Research Ethics Committee(JREC); Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, India: BJ Government College CTU Ethics Committee and Johns Hopkins IRB; Blantyre, Malawi: College of Medicine Research and Ethics Committee (COMREC) in Malawi, Pharmacy, Medicines and Poisons Board and Johns Hopkins Medical Institutions (JHMI) IRB in the U.S.; Lilongwe, Malawi: National Health Sciences Research Committee (NHSRC) in Malawi Pharmacy, Medicines and Poisons Board, and University of North Carolina, Chapel Hill (UNC-CH) Office of Human Research Ethics IRB in the U.S and Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania: Kilimanjaro Christian Medical College Ethics Committee, National Health Research Ethics Committee and Tanzania Medicines and Medical Devices Authority.
The primary outcome measure was percent change in lumbar spine (LS) BMD assessed by DXA between baseline and week 74. A secondary outcome measure was percent change in hip BMD from baseline to week 74. Primary analyses were carried out by randomized assignment for the mothers included in the analysis, as were secondary analyses on additional DXA outcome measures. Selected subgroup and restricted/as-treated analyses were performed as secondary analyses. Percent change in maternal LS BMD and hip BMD were analyzed with Student t-tests (two-sided) to compare the maternal TDF-ART and iNVP arms. The TDF-ART versus iNVP effect was adjusted for covariates and effect modification by subgroups (interaction tests) was assessed via linear regression. Covariates included at postpartum randomization (baseline): age, weight, parity at PROMISE entry, HIV RNA level, country, and antepartum randomization assignment. Additional comparisons applied Wilcoxon/Kruskal-Wallis test for continuous data, and χ2/exact tests for categorical data, as appropriate. Analyses were performed using SAS v9.4 (Cary, NC). Statistical significance was set at the 0.05 level, with no adjustment for multiple comparisons.
The data cannot be made publicly available due to the ethical restrictions in the study’s informed consent documents and in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network’s approved human subjects protection plan; public availability may compromise participant confidentiality. However, data are available to all interested researchers upon request to the IMPAACT Statistical and Data Management Centre’s data access committee by email to email@example.com or firstname.lastname@example.org. This committee reviews and responds to requests for data, obtains necessary approvals from IMPAACT leadership and the NIH, arranges for signature of a Data Use Agreement, and releases the requested data.
Of 2431 mother-infant pairs randomized into the PROMISE Postpartum Component, 592 without prior TDF exposure were randomized at the four participating sites during the sub-study enrolment period. Four hundred mother-infant pairs (202 and 198 pairs previously randomized to TDF-ART and iNVP, respectively) co-enrolled (68%) into the postpartum P1084s sub-study between August 2011 and October 2012 (Fig 1).
There were no eligibility violations. Per the P1084s protocol and analysis plan, the primary analysis excluded two participants in the TDF-ART arm whose initial ART regimen after postpartum randomization was not a TDF-containing regimen. Among the 398 mothers included in the analysis, 374 (94%) completed the P1084s study follow-up. Twenty-two (6%) mothers discontinued the P1084s sub-study before completing the week 74 visit with 12 (6%) from the maternal TDF-ART arm and 10 (5%) from the iNVP arm, with no apparent differences in reasons for discontinuation. There was one maternal death in each arm. One hundred and fifty-eight women (90% of those with week 74 lumbar spine DXA scan) in the iNVP arm remained on their assigned study treatment (no ART) at the time of the week 74 DXA and 17/175 women had begun ART prior to that date (primarily TDF-containing ART regimens). Percent change in BMD from baseline to week 74 was available for lumbar spine (hip) in 337 (336)/398 mothers who had DXA scan data at both time points. They were missing on sixty-two (16%) mothers for reasons of prior study follow-up discontinuation (3.3%), missed week 74 visit (2.5%), DXA scan technical problems (1.0%), and not done due to pregnancy (3.0%),
Mothers were enrolled in Uganda (42%), Zimbabwe (42%), South Africa (10%) and Malawi (7%). The women were co-enrolled after delivery of their first (16%), second (29%), third (26%) or fourth-ninth (29%) pregnancies and all had initiated breastfeeding. Baseline characteristics at sub-study entry for those included in the analysis are presented in Table 1 and were comparable between the study arms (see S1 Table for characteristics of those not co-enrolled). Alcohol use in the 30 days prior to sub-study entry was reported by 12% of participants.
The proportion of sub-study participants who had no antenatal HIV intervention (late presenters to care) was 9%. The median CD4 count in pregnancy at initial PROMISE study entry was 540 cells/mm3 (446–701) with 40% of participants having a CD4 count 350 to <500 cells/mm3. At entry into the sub-study postpartum, 46% had been randomized Antepartum to triple ARV with Zidovudine/Lamivudine/Lopinavir/ritonavir ART, the median CD4 count was 671 cells/mm3 (544.0–855) with CD4 350 to <500 cells/mm3 in 18%. The median HIV-1 viral load was 400 copies/ml (61.5–1314.5) in the maternal TDF-ART arm and 400 copies/ml (142–3182) in the iNVP arm.
During follow-up, use of DMPA injectable contraceptive and duration of breastfeeding were similar between study arms. Two thirds (65%) of mothers started contraceptives and one third had any exposure to injectable contraceptives prior to their week 74 DXA measurement. Half (54%) started their first contraceptive at least 12 months prior to their week 74 DXA scan. Median time to cessation of breastfeeding was 61.4 weeks and 48% of the sample had stopped breastfeeding more than three months before the week 74 DXA scan; at DXA scan for lumbar spine the median (25th, 75th percentile) number of weeks since weaning was 17.29 (9.07–24.71) in the maternal TDF-ART arm and 17.00 (9.86–23.36) in the iNVP arm. By the time data were censored at release of the START study results in June 2015, there had been one traumatic fracture recorded in the maternal TDF-ART arm and no fractures in the iNVP arm after delivery.
Change in bone mineral density
The baseline (week 1) mean BMD at the lumbar spine in the maternal TDF-ART study arm was 0.94 g/cm2 (95%CI 0.93–0.96) and 0.94 g/cm2 (0.92–0.95) in the iNVP arm. At the hip, the baseline mean BMD in the maternal TDF-ART study arm was 0.98 g/cm2 (0.96–0.99) and 0.98 g/cm2 (0.96–1.00) in the iNVP arm.
For the primary outcome measure of percent change in LS BMD (Fig 2), the maternal TDF-ART arm had a greater mean percent change from baseline to week 74 postpartum of -2.05% (95% CI -2.88, -1.22) compared to a mean of +0.81% (-0.01, 1.64) in the iNVP arm, for a mean difference of -2.86% (-4.03, -1.70) (p-value <0.001). Similarly, for the secondary outcome measure of hip BMD, the mean percent change was greater in the maternal TDF-ART arm compared to the iNVP arm; -5.34% (-5.96, -4.73) versus -3.05% (-3.72, -2.38) respectively, for a mean difference of -2.29% (-3.20, -1.39) (p-value<0.001).
Data points and the distributions are summarized with violin plots. Each violin plot presents density, along with horizontal lines indicating quartiles, a red circle for the median and a diamond for the mean (with whiskers for the 95% CI). Individual data points are superimposed on the violin plot.
These treatment effects remained after adjusting for the covariates under consideration, either one at a time (results not shown) or together in a model (p<0.001) (Fig 3). The treatment difference on lumbar spine BMD was larger for those women who were also randomized to ART in the PROMISE antepartum component (p = 0.006). At both lumbar spine and hip the treatment difference was larger for women who weighed less at baseline (p-value< = 0.05). For the secondary outcome measure of hip BMD the treatment difference was larger for younger women (p = 0.03). The treatment effect did not appear to differ by country, breastfeeding or contraception status at either location (p≥0.55). The mean difference in percent BMD change at the lumbar spine in Malawi did appear to be smaller than that seen in other countries for the primary endpoint (-0.70) although the 95%CI was wide (-5.63, 4.23). The effect of ART exposure on BMD at the lumbar spine and hip remained in sensitivity analyses, among women who were still breast feeding or on their assigned treatment at the time of the week 74 DXA scan.
Percent change to week 74 in (A) spine BMD (primary outcome measure) and (B) hip BMD: maternal TDF-ART vs. iNVP treatment effect modification by covariate.
Among 264 participants who had ceased breast feeding before week 74, the mean percent change in LS BMD was -1.39 in the mART arm and -1.31 in the iNVP arm (mean difference (95%CI) -2.71 (-4.00, -1.41). Among the 236 participants who were on their assigned treatment at week 74 (on TDF in the maternal arm, no ARVs in the iNVP arm) the mean percent change in LS BMD was -3.73 in the maternal TDF- and 1.11 in the iNVP arm (mean difference (95% CI) -4.84 (-6.25, -3.43)).
Within a large randomized PMTCT clinical trial among asymptomatic African mothers with HIV and high CD4 counts who breastfed on average for longer than one year, we found mothers randomized postpartum to TDF-ART BMD during breastfeeding experienced a greater BMD decline at the lumbar spine between postpartum weeks 1 and 74 when compared to women who did not receive maternal ART. Our primary analysis included randomized participants who signed up for the substudy. Selection, confounding bias and bias due to drop-out appeared to be small. The overall estimated treatment difference includes participants who subsequently changed their initially assigned regimen and appears to result in a conservative estimate of the difference. The overall effect of TDF-ART on maternal BMD remained in adjusted and sensitivity analyses.
The negative effect on BMD in women with HIV on TDF-ART and on no ART persisted after the period of lactation had ended, when post-weaning restitution/recovery would have been anticipated. Nabwire et al  also reported partial skeletal recovery with a 2–3% deficit in total hip BMD three months following cessation of breastfeeding among Ugandan women with HIV on Efavirenz-based TDF-ART compared to women living without HIV. Taken together with our findings, bone loss during pregnancy and breastfeeding is potentially exacerbated by TDF-ART. The long-term clinical implication of a 2–3% greater decline in postpartum maternal BMD over 74 weeks in women on TDF-ART is unknown and is smaller than the assumed 5–7% considered of clinical concern in the study design. However, for women with HIV in settings where fertility is high, breastfeeding into the second year post delivery is the norm and where repeated cycles of bone loss/restoration with each pregnancy occur—sometimes at close intervals—the findings raise potential concerns of increased risk for long term bone loss among high parity women on life-long ART. In addition, women in such settings often have additional risk factors that impact bone health, such as undernutrition and predominance of injectable hormonal contraception .
The larger treatment difference on lumbar spine BMD observed in the sub-study women who had been randomly assigned to antepartum ART could reflect a cumulative effect of the ARVs they received while pregnant and during lactation on postpartum bone health. While the specific PI-based ART regimen administered in PROMISE is not widely used in the current era of universal ART, Tenofovir based ART regimens are widely used. Tenofovir exposure increased 20–37% when TDF was co-administered with ritonavir (r), Atazanavir/r, Lopinavir/r, Darunavir/r, or Cobicistat . In the PROMISE trial, the postpartum regimen provided was TDF combined with Emtricitabine and Lopinavir/r. The increased TDF exposure with Lopinavir/r might have led to an increased risk of bone toxicity in the context of this study. Investigations continue to evaluate novel ARVs reported to have less effect on BMD, such as Tenofovir alafenamide  with the view to optimize the safety and efficacy of ART regimens among women of reproductive potential. Our findings relating to the decreased BMD findings post cessation of breastfeeding for those HIV Infected women on TDF-ART remain important, as global HIV programs will continue to use TDF in the near future for HIV treatment and prevention (within PrEP regimens) until alternative regimens have demonstrated favorable safety in women and in pregnancy; and given that use of ART in general has been associated with bone loss.
Relative strengths and limitations
Major strengths of this study design include the randomized trial design, large sample size and inclusion of breastfeeding women living with HIV from multiple sites in Africa. The large sample permitted the detection of small differences between the study arms which is important when a decline of just 5–7% is considered of clinical concern and would trigger clinical management. The TDF-ART association with BMD was not observed to differ across four countries spread across Southern, Central and East Africa which increases the generalizability of our findings. Sub-study participants’ characteristics other than country did not differ substantially at baseline from PROMISE Postpartum component women who did not co-enroll. Likewise, the standardized DXA procedures and blinded centralized readings contributed to robustness and validity of the data. Most notably, maternal ART was initiated following randomization of healthy participants as opposed to following a clinical management decision, alleviating the potential bias present in previous publications of other observational cohorts, alluded to in Bedimo’s systematic review .
A relative study limitation is that 15% of participants were missing data for the primary outcome measure due to not completing follow-up or lacking a week 74 DXA scan. However, frequency and reasons did not differ by study arm and the sample size achieved was able to demonstrate a difference between study arms of 2–3%. We also identifed a number of notable limitations of the study design. Firstly, we assumed breastfeeding cessation would take place 12–15 months postpartum and timed the week 74 DXA scan to occur after BMD restitution was expected to have taken place, but only half of the women had done so in our study. However, the sensitivity analysis performed suggests that the treatment effect of TDF-ART on BMD remained in women who had ceased to breast feed by week 74. Secondly, the ART regimen used in PROMISE was Protease Inhibitor-based TDF-ART. Not having a comparison ART regimen prevents evaluation of the relative roles of each agent in the observed BMD changes and restricts our ability to project what may be expected when TDF is combined with other agents. Nevertheless, TDF use is widespread for HIV treatment and prevention and PI-based TDF-ART remains second-line therapy and in use by large numbers of women globally. Ongoing studies will document the effect on maternal BMD of newer ARVs used for HIV treatment and prevention. In conclusion, this study among HIV-infected breastfeeding women in resource limited settings, demonstrated greater decrease in maternal bone mineral density up to 18 months postpartum among women randomized to TDF-ART compared to infants who were randomized to daily nevirapine prophylaxis during breastfeeding. While this difference may not be of immediate clinical significance, further study is necessary to adequately address whether there is full or only partial recovery of BMD following cessation of breastfeeding and the longer term impact through menopause of repeat pregnancies and extended periods of breastfeeding among women with HIV on life-long ART in resource limited settings. The findings also highlight the need for bone metabolism studies to further elucidate the underlying biologic patterns and mechanisms of bone loss and recovery among mothers on life-long TDF-ART.
S1 Fig. Maternal randomization schema during the PROMISE study for mothers enrolled in the postpartum TDF exposure component of P1084s.
Under version 2.0 of the trial protocol only women who were positive for hepatitis B surface antigen were randomly assigned to tenofovir-based antiretroviral therapy (ART); under (last) version 3.0, all women could be assigned to any of the three regimens (1). P1084s postpartum enrolled completely under PROMISE protocol version 2.0. After delivery, women were randomized to continue or initiate ART or to no ART (2). In a third randomization (not shown) after weaning, eligible women were randomized again to continue ART or to a no ART arm (3). Those who had been previously randomized to no ART were continued on no ART. The first antepartum randomization was Apr. 11, 2011. After the results of the START study in July 2015 (4), all women were recommended to initiate ART. At that time, all P1084s women who enrolled in the Postpartum Exposure Component had discontinued or completed the 74 week follow-up for this substudy. All women who met specific treatment guidelines and all infants who were confirmed to be infected with the human immunodeficiency virus (HIV) began ART immediately. The above schema represents breast-feeding women. AP = Antepartum, IP = intrapartum, PP = postpartum. TDF = tenofovir disoproxil fumarate, FTC = emtricitabine, ZDV = zidovudine, sdNVP = single dose nevirapine.
S1 Table. Baseline characteristics by P1084s Co-enrollment.
The PROMISE study team gratefully acknowledges the dedication and commitment of the mother-infant pairs without whom this study would not have been possible. We acknowledge the research teams at each of the participating sites: PROMISE Study Team Members: Judith Currier, Katherine Luzuriaga, Adriana Weinberg, James McIntyre, Tsungai Chipato, Karin Klingman, Renee Browning, Mireille Mpoudi-Ngole, Jennifer S. Read, George Siberry, Heather Watts, Lynette Purdue, Terrence Fenton, Linda Barlow-Mosha, Mary Pat Toye, Mark Mirochnick, William B. Kabat, Benjamin Chi, Marc Lallemant, Karin Nielsen; Statistical and Data Analysis Center, Harvard T.H. Chan School of Public Health: Kevin Butler MS, Konstantia Angelidou MS, David Shapiro, and Sean Brummel. IMPAACT Operations Center: Anne Coletti, Veronica Toone, Megan Valentine, Kathleen George; Frontier Science Data Management Center: Amanda Zadzilka, Michael Basar, Amy Jennings, Adam Manzella.
INDIA. Sandesh Patil; Ramesh Bhosale; Neetal Nevreka
MALAWI. Blantyre: Salome Kunje; Alex Siyasiya, Certificate in Microbiology; Mervis Maulidi. Lilongwe/UNC: Francis Martinson; Ezylia Makina; Beteniko Milala.
SOUTH AFRICA. Durban Paediatric: Nozibusiso Rejoice Skosana; Sajeeda Mawlana, MBChB Family Clinical Research Unit: Jeanne Louw; Magdel Rossouw; Lindie Rossouw. Shandukani Research: Masebole Masenya; Janet Grab. Soweto: Nasreen Abrahams; Mandisa Nyati; Sylvia Dittmer. Umlazi CRS: Dhayendre Moodley; Vani Chetty; Alicia Catherine Desmond.
TANZANIA. Kilimanjaro Christian Medical Centre: Boniface Njau; Cynthia Asiyo; Pendo Mlay.
UGANDA. MU-JHU Research Collaboration: Maxensia Owor; Moreen Kamateeka; Dorothy Sebikari.
ZAMBIA. George Clinic: Felistas M. Mbewe; Martin Mwalukanga.
ZIMBABWE. Harare Family Care: Tichaona Vhembo; Nyasha Mufukari. Seke North: Lynda Stranix-Chibanda; Teacler Nematadzira; Gift Chareka. St. Mary’s: Jean Dimairo; Tsungai Chipato; Bangani Kusakara; Mercy Mutambanengwe; Emmie Marote.
- 1. Kalkwarf H. and Specker B., “Bone mineral changes during pregnancy and lactation,” Endocrine, vol. 17, no. 1, pp. 49–53, Feb. 2002, pmid:12014704
- 2. Kovacs C. S., “Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery,” Physiol. Rev., vol. 96, no. 2, pp. 449–547, Feb. 2016, pmid:26887676
- 3. Chitu-Tisu C.-E., Barbu E.-C., Lazar M., Ion D. A., and Anca I., “Original article Low bone mineral density and associated risk factors in HIV-infected patients,” GERMS, vol. 6, no. 2, pp. 50–59, 2016. pmid:27482514
- 4. Mondy K. et al., “Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.,” Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 36, no. 4, pp. 482–490, 2003, pmid:12567307
- 5. Kooij K. W. et al., “Low Bone Mineral Density in Patients With Well-Suppressed HIV Infection: Association With Body Weight, Smoking, and Prior Advanced HIV Disease,” Ournal Infect. Dis., vol. 211, pp. 539–548, 2015, pmid:25180239
- 6. da S D. C.. Chaba et al., “Low bone mineral density among HIV-infected patients in Brazil,” Rev. Inst. Med. Trop. São Paulo, vol. 59, p. e89, 2017, pmid:29267597
- 7. Assoumou L. et al., “Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.,” AIDS Lond. Engl., vol. 27, no. 15, pp. 2425–2430, Sep. 2013, pmid:24029735
- 8. Rivas P., Gorgolas M., Garcia-Gelgado R., Diaz-Curiel M., Goyenechea A., and Fernandez-Guerrero M. L., “Evolution of bone mineral density in AIDS patients on treatment with zidovudine / lamivudine plus abacavir or lopinavir / ritonavir,” HIV Med., vol. 9, pp. 89–95, 2008, pmid:18093130
- 9. Gomes D. C., Valadares A. L. R., Amaral E., Ferreira N. D. O., and Pinto-neto A. M., “Association between HIV infection and bone mineral density in climacteric women,” Arch. Osteoporos., vol. 10, p. 33, 2015, pmid:26420601
- 10. Mondy K. and Tebas P., “Emerging bone problems in patients infected with human immunodeficiency virus,” Clin Infect Dis, vol. 36, no. Suppl 2, pp. S101–5, 2003, pmid:12652379
- 11. Dolan S. E., Huang J. S., Killilea K. M., Sullivan M. P., Aliabadi N., and Grinspoon S., “Reduced bone density in HIV-infected women,” AIDS, vol. 18, no. 3, 2004, [Online]. Available: https://journals.lww.com/aidsonline/Fulltext/2004/02200/Reduced_bone_density_in_HIV_infected_women.14.aspx. pmid:15090800
- 12. Hoy J. F. et al., “Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial,” J. Bone Miner. Res., vol. 32, no. 9, pp. 1945–1955, Jun. 2017, pmid:28650589
- 13. Brown T. T., McComsey G. A., King M. S., Qaqish R. B., Bernstein B. M., and da Silva B. A., “Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen:,” JAIDS J. Acquir. Immune Defic. Syndr., vol. 51, no. 5, pp. 554–561, Aug. 2009, pmid:19512937
- 14. Huang J. S., Hughes M. D., Riddler S. A., Haubrich R. H., and AIDS Clinical Trials Group A5142 Study Team, “Bone Mineral Density Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor Selection from ACTG A5142,” HIV Clin. Trials, vol. 14, no. 5, pp. 224–234, Oct. 2013, pmid:24144899
- 15. Dave J., Cohen K., Micklesfield L., Maartens G., and Levitt N., “Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.,” PLoS ONE, vol. 10, no. 12, p. e0144286, Dec. 2015, https://doi.org/10.1371/journal.pone.0144286 pmid:26633015
- 16. Moran C. A., Weitzmann M. N., and Ofotokun I., “The protease inhibitors and HIV-associated bone loss,” Curr. Opin. HIV AIDS, vol. 11, no. 3, pp. 333–342, May 2016, pmid:26918650
- 17. Purdy J. B., Gafni R. I., Reynolds J. C., Zeichner S., and Hazra R., “Decreased Bone Mineral Density with Off-Label Use of Tenofovir in Children and Adolescents Infected with Human Immunodeficiency Virus,” J. Pediatr., vol. 152, no. 4, pp. 582–584, Apr. 2008, pmid:18346519
- 18. Mccomsey G. A. et al., “Switch from tenofovir disoproxil fumarate combination to dolutegravir plus rilpivirine improves parameters of bone health:,” AIDS, p. 1, Dec. 2017, pmid:27755112
- 19. DeJesus E. et al., “Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment,” AIDS Res. Hum. Retroviruses, vol. 34, no. 4, pp. 337–342, Jan. 2018, pmid:29368537
- 20. Maggiolo F. et al., “Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial,” Lancet HIV, vol. 6, no. 10, pp. e655–e666, Oct. 2019, pmid:31578954
- 21. Mirembe B. G. et al., “Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.,” J. Acquir. Immune Defic. Syndr. 1999, vol. 71, no. 3, pp. 287–294, Mar. 2016, pmid:26866954
- 22. Mulligan K. et al., “Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial,” Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 61, no. 4, pp. 572–580, Aug. 2015, pmid:25908682
- 23. Gill U. S. et al., “Factors determining bone mineral density loss in chronic hepatitis B patients: is tenofovir disoproxil fumarate the main culprit?,” Gut, vol. 60, no. Suppl 1, p. A230, Apr. 2011,
- 24. Buti M. and Homs M., “Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B,” Expert Rev. Gastroenterol. Hepatol., vol. 6, no. 4, pp. 413–421, Aug. 2012, pmid:22928893
- 25. Erlandson K. M. et al., “Bone Mineral Density Declines Twice as Quickly Among HIV-Infected Women Compared With Men:,” JAIDS J. Acquir. Immune Defic. Syndr., vol. 77, no. 3, pp. 288–294, Mar. 2018, pmid:29140875
- 26. Orlic Z. C. and Raisz L. G., “Causes of Secondary Osteoporosis,” J. Clin. Densitom., vol. 2, no. 1, pp. 79–92, 1999, pmid:23547317
- 27. Sharma N., Natung T., Barooah R., and Ahanthem S. S., “Effect of Multiparity and Prolonged Lactation on Bone Mineral Density,” J. Menopausal Med., vol. 22, no. 3, pp. 161–166, Dec. 2016, pmid:28119896
- 28. Polatti F., Capuzzo E., Viazzo F., Colleoni R., and Klersy C., “Bone mineral changes during and after lactation,” Obstet. Gynecol., vol. 94, no. 1, pp. 52–56, Jul. 1999, pmid:10389717
- 29. Cooke-Hubley S., Kirby B., Valcour J., Mugford G., Adachi J., and Kovacs C. S., “Spine bone mineral density increases after 6 months of exclusive lactation, even in women who keep breastfeeding,” Arch. Osteoporos., no. 12, p. 73, Dec. 2017, https://doi.org/10.1007/s11657-017-0368-6 pmid:28815389
- 30. Laskey M. A. and Prentice A., “Bone mineral changes during and after lactation,” Obstet. Gynecol., vol. 94, no. 4, pp. 608–615, Oct. 1999. pmid:10511368
- 31. Kalkwarf H. J. and Specker B. L., “Bone mineral loss during lactation and recovery after weaning,” Obstet. Gynecol., vol. 86, no. 1, pp. 26–32, Jul. 1995, pmid:7784018
- 32. Weitzmann M. N., Ofotokun I., Titanji K., Sharma A., and Yin M. T., “Bone Loss Among Women Living With HIV,” Curr. HIV/AIDS Rep., vol. 13, no. 6, pp. 367–373, Dec. 2016, pmid:27678124
- 33. Mori T. et al., “Parity, lactation, bone strength, and 16-year fracture risk in adult women: findings from the Study of Women’s Health Across the Nation (SWAN),” Bone, vol. 73, pp. 160–166, Apr. 2015, pmid:25528102
- 34. Kovacs C. S., “The Skeleton Is a Storehouse of Mineral That Is Plundered During Lactation and (Fully?) Replenished Afterwards,” J. Bone Miner. Res., vol. 32, no. 4, pp. 676–680, Feb. 2017, pmid:28177150
- 35. Bjørnerem Å. et al., “Irreversible Deterioration of Cortical and Trabecular Microstructure Associated With Breastfeeding,” J. Bone Miner. Res., vol. 32, no. 4, pp. 681–687, Oct. 2016, pmid:27736021
- 36. Matovu F. K., Wattanachanya L., Beksinska M., Pettifor J. M., and Ruxrungtham K., “Bone health and HIV in resource-limited settings: a scoping review,” Curr. Opin. HIV AIDS, vol. 11, no. 3, pp. 306–325, May 2016, pmid:27023284
- 37. Nabwire F. et al., “Changes in Bone Mineral Density During and After Lactation in Ugandan Women With HIV on Tenofovir-Based Antiretroviral Therapy,” J. Bone Miner. Res., vol. n/a, no. n/a, Jun. 2020, pmid:32573842
- 38. Flynn P. M. et al., “Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE),” JAIDS J. Acquir. Immune Defic. Syndr., vol. 77, no. 4, pp. 383–392, Apr. 2018, pmid:29239901
- 39. Fowler M. et al., “Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention,” N. Engl. J. Med., vol. 375, no. 18, pp. 1726–1737, Nov. 2016, pmid:27806243
- 40. T. Taha, “Comparing maternal triple antiretrovirals (mART) and infant nevirapine (iNVP) prophylaxis for the prevention of mother-to-child transmission (MTCT) of HIV during breastfeeding (BF),” presented at the 21st International AIDS Conference (AIDS 2016), Durban, South Africa, Jul. 2016.
- 41. Currier J. S. et al., “Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm(3),” PLoS ONE, vol. 12, no. 5, p. e0176009, 2017, pmid:28489856
- 42. INSIGHT START Study Group, Lundgren J., and Babiker A., “Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection,” N. Engl. J. Med., vol. 373, no. 9, pp. 795–807, Jul. 2015, pmid:26192873
- 43. F. K. Matovu et al., “Depo-Provera worsens bone loss with TDF-containing ART initiation in young women.,” in Abstract Supplement Oral Abstracts from the 23rd International AIDS Conference, Virtual, Jul. 2020, vol. OAB0105, https://doi.org/10.1002/jia2.25547.
- 44. Bedimo R., Rosenblatt L., and Myers J., “Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection,” HIV Clin. Trials, vol. 17, no. 6, pp. 246–266, Nov. 2016, pmid:27809711
- 45. Sax P. E. et al., “Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials,” The Lancet, vol. 385, no. 9987, pp. 2606–2615, Jun. 2015,